Scrip - Pharma News And Expert Analysis For Commercial Decision Makers since 1972


Spotlight on Scrip Perspectives 24/25





Focus On Asia


Data Analysis


R&D


Inventiva Tries Restructuring To Reach Phase III Finish Line In MASH

 
• By 

Large headcount reduction and ending preclinical programs may give Inventiva runway to report Phase III data for lanifibranor that are expected during the second half of 2026.

Vertex Is Firing On All Cylinders But New Drug Launches Remain Challenging

 

As the architect of the company’s hugely successful business model, Stuart Arbuckle, departs, he hands over a portfolio expanding beyond its cystic fibrosis base, but one that might be slow to build revenues for Casgevy and Journavx.

Novartis Welcomes Abelacimab Back Into The Fold With Anthos Acquisition

 
• By 

The Swiss major may have to pay over $3bn for the dual-acting Factor XI/XIa inhibitor that it originally developed before the drug was passed on to Anthos Therapeutics, founded by private equity firm Blackstone and the Swiss major in 2019.

Aurobindo: US Tariffs “Not A Challenge” For Now, Scouting For Biosimilars Tie-Ups

 
• By 

A US tariff on imports from China raises the spectre of similar action against India, but Aurobindo, the largest generics company in the US by prescriptions dispensed, assures it has alternatives in place. While trials for an opthalmology biosimilar are delayed, supply of other biosimilars to Europe is set to begin in Q2 FY26

Business


Finance Watch: Third Harmonic, Q32 Bio Cut Jobs To Focus On Lead Assets

 
• By 

Restructuring Edition: Third Harmonic cut its workforce by half based on positive Phase I data for THB335. Also, encouraged by early Phase IIa results in alopecia areata, Q32 Bio is focusing on bempikibart. In addition, X4, Turnstone, Fractyl, Cargo and others recently revealed layoffs.

How To Work With Trump, The Future Of US Life Sciences And More: Updates From BIO CEO & Investor

 

Highlights from the BIO CEO & Investor Conference, held in New York 10-11 February, include the impact of US political changes, Chinese companies entering the obesity race, and IPO pitfalls.

Inventiva Tries Restructuring To Reach Phase III Finish Line In MASH

 
• By 

Large headcount reduction and ending preclinical programs may give Inventiva runway to report Phase III data for lanifibranor that are expected during the second half of 2026.

Vertex Is Firing On All Cylinders But New Drug Launches Remain Challenging

 

As the architect of the company’s hugely successful business model, Stuart Arbuckle, departs, he hands over a portfolio expanding beyond its cystic fibrosis base, but one that might be slow to build revenues for Casgevy and Journavx.

Scrip Originals


Finance Watch: Third Harmonic, Q32 Bio Cut Jobs To Focus On Lead Assets

 
• By 

Restructuring Edition: Third Harmonic cut its workforce by half based on positive Phase I data for THB335. Also, encouraged by early Phase IIa results in alopecia areata, Q32 Bio is focusing on bempikibart. In addition, X4, Turnstone, Fractyl, Cargo and others recently revealed layoffs.

Stock Watch: Global Issues Sway Big Pharma Stocks In Q4 Earnings Season

 
• By 

Taking a broad view of big pharma share price movements as the sector reported 2024 financials, company-specific issues were complicated by geopolitical factors including Donald Trump’s tariff announcements.

Pipeline Watch: Six Approvals And Five Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Executives On The Move: Two CMOs And Two CEOs and CFOs Each Among This Week’s Changes

Recent moves in the industry include C-suite changes at Ironwood Pharmaceuticals and Procaps Group, plus Viracta Therapeutics acquires chief executive officer from Molecular Templates.